LENZ Therapeutics Reports Q4 2025 Financial Results
Ticker: LENZ · Form: 8-K · Filed: Mar 24, 2026 · CIK: 0001815776
| Field | Detail |
|---|---|
| Company | Lenz Therapeutics, Inc. (LENZ) |
| Form Type | 8-K |
| Filed Date | Mar 24, 2026 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: earnings, financial-results, 8-K, press-release
TL;DR
**LENZ Therapeutics just dropped their latest financial results, so expect some stock movement.**
AI Summary
LENZ Therapeutics, Inc. filed an 8-K on March 24, 2026, under Item 2.02, indicating they are reporting "Results of Operations and Financial Condition." This filing includes an exhibit, EX-99.1, which is likely a press release detailing their financial performance. This matters to investors because it provides the latest financial health update, which could influence the stock price based on whether the results meet or miss expectations.
Why It Matters
This filing provides investors with crucial financial performance data, allowing them to assess the company's health and make informed decisions about buying, holding, or selling the stock.
Risk Assessment
Risk Level: medium — The risk is medium because financial results can cause significant stock price volatility depending on whether they beat or miss analyst expectations.
Analyst Insight
A smart investor would review the attached EX-99.1 press release to understand the specific financial results, compare them against analyst expectations, and assess the company's future outlook before making any investment decisions.
Key Players & Entities
- LENZ Therapeutics, Inc. (company) — the filer of the 8-K
- 0001815776 (company) — CIK of LENZ Therapeutics, Inc.
- 2026-03-24 (date) — filing date and period of report
FAQ
What specific financial information is included in this 8-K filing?
The 8-K filing, under Item 2.02, indicates 'Results of Operations and Financial Condition.' It also includes an exhibit, EX-99.1, which is described as 'a991q425pressrelease.htm', strongly suggesting a press release detailing their financial performance for the period ending December 31, 2025 (given the 'Q425' in the filename).
What is the purpose of an 8-K filing for 'Results of Operations and Financial Condition'?
An 8-K filing for 'Results of Operations and Financial Condition' (Item 2.02) is used by companies to announce their financial results for a completed fiscal quarter or year, often through a press release, before their full 10-Q or 10-K report is filed. This provides timely disclosure of material financial information to investors.
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2026-03-24 08:10:40
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share LENZ The Nasdaq Stock Market
Filing Documents
- lenz-20260324.htm (8-K) — 27KB
- a991q425pressrelease.htm (EX-99.1) — 99KB
- lenzlogo.jpg (GRAPHIC) — 3KB
- 0001815776-26-000008.txt ( ) — 259KB
- lenz-20260324.xsd (EX-101.SCH) — 2KB
- lenz-20260324_lab.xml (EX-101.LAB) — 23KB
- lenz-20260324_pre.xml (EX-101.PRE) — 13KB
- lenz-20260324_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 24, 2026 , LENZ Therapeutics, Inc. issued a press release announcing its financial results for the fiscal year ended December 31, 2025 . A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. All of the information furnished in this Item 2.02 and the press release attached hereto as Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated March 24 , 202 6 . 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 24, 2026 LENZ THERAPEUTICS, INC. By: /s/ Daniel Chevallard Name: Daniel Chevallard Title: Chief Financial Officer